164 related articles for article (PubMed ID: 38043684)
21. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
Wu D; Li M
Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
[TBL] [Abstract][Full Text] [Related]
22. Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics - a case study and utility in regulatory justifications.
Boddu R; Kollipara S; Bhattiprolu AK; Ahmed T
Xenobiotica; 2023; 53(10-11):587-602. PubMed ID: 38062540
[TBL] [Abstract][Full Text] [Related]
23. Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
Heimbach T; Suarez-Sharp S; Kakhi M; Holmstock N; Olivares-Morales A; Pepin X; Sjögren E; Tsakalozou E; Seo P; Li M; Zhang X; Lin HP; Montague T; Mitra A; Morris D; Patel N; Kesisoglou F
AAPS J; 2019 Feb; 21(2):29. PubMed ID: 30746576
[TBL] [Abstract][Full Text] [Related]
24. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets.
Jaiswal S; Ahmed T; Kollipara S; Bhargava M; Chachad S
Drug Dev Ind Pharm; 2021 May; 47(5):778-789. PubMed ID: 34082622
[TBL] [Abstract][Full Text] [Related]
25. Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254).
Stamatopoulos K; Ferrini P; Nguyen D; Zhang Y; Butler JM; Hall J; Mistry N
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839843
[TBL] [Abstract][Full Text] [Related]
26. Physiologically Based Biopharmaceutics Modeling of Food Effect for Basmisanil: A Retrospective Case Study of the Utility for Formulation Bridging.
Belubbi T; Bassani D; Stillhart C; Parrott N
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678820
[TBL] [Abstract][Full Text] [Related]
27. Dissolution Profiles of Generic Products in Dissolution Media Defined by Japanese Guidelines for Bioequivalence Studies.
Kajiwara E; Kamizato H; Shikano M
Ther Innov Regul Sci; 2021 Sep; 55(5):1096-1100. PubMed ID: 34097289
[TBL] [Abstract][Full Text] [Related]
28. Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report.
Pepin XJH; Parrott N; Dressman J; Delvadia P; Mitra A; Zhang X; Babiskin A; Kolhatkar V; Suarez-Sharp S
J Pharm Sci; 2021 Feb; 110(2):555-566. PubMed ID: 32380182
[TBL] [Abstract][Full Text] [Related]
29. Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification.
Pepin X; McAlpine V; Moir A; Mann J
Mol Pharm; 2023 Apr; 20(4):2181-2193. PubMed ID: 36859819
[TBL] [Abstract][Full Text] [Related]
30. Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space - Part I: Adults.
Pepin XJH; Hammarberg M; Mattinson A; Moir A
Pharm Res; 2023 Feb; 40(2):387-403. PubMed ID: 36002614
[TBL] [Abstract][Full Text] [Related]
31. Biopharmaceutics classification system-based biowaivers for generic oncology drug products: case studies.
Tampal N; Mandula H; Zhang H; Li BV; Nguyen H; Conner DP
AAPS PharmSciTech; 2015 Feb; 16(1):5-9. PubMed ID: 25245330
[TBL] [Abstract][Full Text] [Related]
32. Development of Extended-Release Mini-Tablets Containing Metoprolol Supported by Design of Experiments and Physiologically Based Biopharmaceutics Modeling.
Issa MG; de Souza NV; Jou BWC; Duque MD; Ferraz HG
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631478
[TBL] [Abstract][Full Text] [Related]
33. Modelling Based Approaches to Support Generic Drug Regulatory Submissions-Practical Considerations and Case Studies.
Karnati P; Murthy A; Gundeti M; Ahmed T
AAPS J; 2023 Jun; 25(4):63. PubMed ID: 37353655
[TBL] [Abstract][Full Text] [Related]
34. Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary.
Tsakalozou E; Mohamed MF; Polak S; Heimbach T
AAPS J; 2023 Oct; 25(6):96. PubMed ID: 37783902
[TBL] [Abstract][Full Text] [Related]
35. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
[TBL] [Abstract][Full Text] [Related]
36. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
[TBL] [Abstract][Full Text] [Related]
37. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
[TBL] [Abstract][Full Text] [Related]
38. Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol.
Macwan JS; Fraczkiewicz G; Bertolino M; Krüger P; Peters SA
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):622-632. PubMed ID: 34080804
[TBL] [Abstract][Full Text] [Related]
39. Approaches of formulation bridging in support of orally administered drug product development.
Han M; Xu J; Lin Y
Int J Pharm; 2022 Dec; 629():122380. PubMed ID: 36368608
[TBL] [Abstract][Full Text] [Related]
40. Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039.
Kourentas A; Gajewska M; Lin W; Dhareshwar SS; Steib-Lauer C; Kulkarni S; Hirsch S; Heimbach T; Mueller-Zsigmondy M
AAPS J; 2023 Feb; 25(1):25. PubMed ID: 36788163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
